AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
2009 · Cancer Cell · 1,231 citations
https://doi.org/10.1016/j.ccr.2009.09.028
C
Christopher A. Eide
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
372
Papers
10.2K
Citations
38
h-index
76
i10-index
Christopher A. Eide is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Chronic Myeloid Leukemia Treatments & Acute Myeloid Leukemia Research & Chronic Lymphocytic Leukemia Research. The author has an h-index of 38, co-authored 317 publications.
ORCID: 0000-0001-8835-8928Papers by this author
worksResponse and Resistance to BCR-ABL1-Targeted Therapies
2020 · Cancer Cell · 491 citations
https://doi.org/10.1016/j.ccell.2020.03.006
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
2022 · Cancer Cell · 336 citations
https://doi.org/10.1016/j.ccell.2022.07.002
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia
2017 · Cell Reports · 257 citations
https://doi.org/10.1016/j.celrep.2017.03.018
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
2019 · Nature Communications · 148 citations
https://doi.org/10.1038/s41467-018-08263-x
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells
2020 · Signal Transduction and Targeted Therapy · 33 citations
https://doi.org/10.1038/s41392-019-0102-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat